Visfatin and Gestational, Type 1 and Type 2 Diabetes Mellitus: A Review of Literature

Ekpe EL, Omotoso Ayodele

Abstract


Background: Adipose tissues produce adipocytokines and other various substances that have useful actions in the body. One of such adipocytokines is visfatin which has been linked to diabetes mellitus. Aim: This study aimed at investigating the existence of a probable correlation between plasma levels of visfatin and the various types of diabetes mellitus: type 1, type 2 and gestational diabetes mellitus. Methods: A comprehensive literature search was performed using the Internet search engines linked to academic databases including Pubmed, Google Scholar, Ebsco, Hinari, etc. Studies involving visfatin were thoroughly searched and the references of such articles were also searched for any probable relevant information. Results/Findings: There is no agreed finding regarding the correlation between visfatin and diabetes mellitus. While some authors believed that plasma visfatin levels are elevated in diabetes mellitus, others believed that the contrary might be true. Conclusion: Various studies conducted so far have contrasting opinions about the correlation between plasma visfatin levels and diabetes mellitus.

 

 


Keywords


Visfatin; Diabetes mellitus; Gestational; Adipocytokines; Adipose tissue

Full Text:

PDF

References


Pedro Saddi-Rosa, Carolina SV Oliveira, Fernando MA, Andre FR. visfatin, glucose metabolism and vascular disease: Diabetelogy and metabolic syndrome 2012; 2:21

Adeghate E: Visfatin structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem 2008; 15 (18): 1851-62.

Eid M El-Shafey, Gamal F, El-Nagger Mohammed M Al-Bedewy, Hesham -EL- Sorogy. Is there a relationship between visfatin level and type 2 diabetes mellitus in obese and non-obese patients?J diabetes metab 2012; S11:001.

Fasshauer M. Bluher M. Adipokines in health and disease- Trends in pharmacological science 2015;36 (7):461-470.

Anders HB,Terry PC,Philip ES.ACR30/adiponectin:an adipokinee regulating glucose and lipid metabolism.Trends in endocrinology and metabolism.2002;13(2):84-89

Al-Suhaimi E, Shehzal Adeeb. Leptin, resistin and Visfatin: The missing link between endocrine metabolic disorders and immunity. European journal of medical research 2013;18:12.

Sowers JR. Endocrine function of adipose tissues:focus on adiponectin.Clin cornerstone.2008;9(1):32-8

Fukuhara A, Matsuda M, Nishizawa M. Visfatin, a protein secreted by visceral fat that mimics…………--- Science 2005; 307:426-30.

Luk T, Malam Z, Marshall JC. Pre-B cell colony factor (PBEF)/Visfatin- A novel mediator of innate immunity. J Leukol Biol 2008; 83(4): 804-16.

Wang T, Zhang X, Bheda P, Revello JR, Imai S, Wolberger C. Structure of Nampt/PBEF/ visfatin- a mammalian NAD+biosynthesis enzyme: Nat struct mol Biol 2006;13(7): 2.

Jia SH, Li Y, Parodo J. Pre- B cell colony enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-27.

Revello JR, Korner A, Millo KF. Nampt/PBEF/Visfatin regulates insulin secretion in B-cells as a systemiz NAD monosynthetic enzyme. Cell metabolism 2007; 6 (5):363-375.

Dahl TB, Yndestad A, Skgelland, Dahl A, Daras JK. increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Circulation 2007; 5 (8): 972-980.

Chen MP, Chung FM, Chang DM. Elevated plasma levels of visfatin/Pre-B colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrin 2006; 91 (1):295-9

Haider D, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentration in morbidly obese subjects are reduced after gastric banding J Clin Endocrinol Metab in year 91:(1578-1589).

Filipatos TD, Derdemezie CS, Gazi IF. Increased plasma visfatin levels in subject with metabolic syndrom.Eur J Clin Invest 2008; 38:71-72.

Takebayashi R, SuetSugu M, Wakabayashi S, Aso Y, Inukai T. association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes melitus Metabolism 2007; 56(4):451-8.

Zhang M, Tant W, Gong HP. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clinical Endocrinology 2008; 69 (6): 878-884.

Jawar MH, Baranova A. Intracellular NAMPT- NAD+-SIRT1 cascade improve post ischaemic vascular repair by modulating. Cardiovascular Research 2014.

De Luis DA Aller R, Gonzalez Sagrado M, Izaola O, Perez Castrillon, Romeo E. Serum visfatin concerntrations are related to dietary intake in obese patients. Ann Nutr Metab 2010; 57(3-40):265-270.

Jieyu H, Chao T, Menguin L, Shalong W,Xiomei G,Jianfeng, Zihong L. NAMPT/visfsatin/PBEF:a functional multi-faceted protein with a pivotal role in malignant tumors. Curr Pharm Des.2012;18(37):6123-32

Lopez Barmejo, Chico-julia B. Fernandez M, Recasens M., Estere S. Serum visfatin increases with progressive beta-cell deterioration Diabetes; 2006;55(10):2871-5.

Toruner F, Altinova AE, Arslan E, Akbay E, Ersey R. Plasma visfatin concentration in subjects with type 1 diabetes mellitus. Horm Res. 2009; 72(1):33-7

Hong EG, Jung DY, Ko HU, Zhang Z, Ma Z, Jun JY. Non-obese, insulin-deficient Ins2Akita mice develop type 2diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 2007;1687-96

Kang YS, Cha DR. The role of visfatin in diabetic nephropathy. Chonnam Med J.2011;47(3):139-143

Grusubraminian G, Roy VK. Expression of visfatin in alloxan- induced diabetic rat testis. Acta Histochem.2014; 16(8):1462-8

Katwa LC, Seidel ER. Visfatin in prgenacy:proposed mechanism of peptide delivery.Amino acids,2009;37(4):555-8

Kaygusuz I, Gummus ,Yilmaz S,Simavli S,Uysal S,Derbent AU,Kafali H.serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus. Gynecol Obstet Inves.2013; 75(3):203-9

Dahl TB, Holm S,Aukrus Pal,Halvorsen B.Visfatin /NAMPT: A multifaceted molecule with Diverse Roles in physiology and pathophysiology.2012;32:229-243

Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M. Nicotinamide phosphoribosyltransferase/ Visfatin does not catalyze mononucleotide formation in blood plasma.2011.PloS ONE.6(8):e22781

Liang, Wu Y, Xu I. Correlations of serum visfatin and metabolism of glucose and lipid and metabolism of glucose and lipid in women gestational diabetes mellitus 2015.Journal of Diabetes Investigation. Liang X, Wu Ying, Xu J, Fang D.journal Of Diabetes Investigation.2015;7(2):247-252.

Krzyanowaski K, Krugluger W, Mittermayer F, Rahman R Haider D, Shnawa N

Increased visfatin concentration in women with gestational diabetes mellitus. Clin Sc. 2006;11(5): 605-9.

Gok DE, Yazici M, Uckaya G, Bolu SE, Basaran Y. The Role of visfatin in the pathogenesis of gestational diabetes mellitus. Journal of endocrinological Investigation; 2011; 34(1):3-7

Rezvan N, Hosseinzadeh –MJ, Masoud kabir F. Moini A, Janani L, Mazerherion M. Serum visfatin concentration in gestational diabetes mellitus and normal pregnancy. Arch Gynecol Obstet 2012;285(5):1257-62

Park S, Kim MY, Balk SH, Woo J T, Dah, JW. Gestational diabetes is associated with high energy and saturated fat intake and with low plasma visfatin and adiponectin levels independent of pregnancy BMI. European Journal of Clinical Nutrition. 2013; 67:196-281

Kiran G, Kilinc M, Arikan DC. Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus. The Journal of maternal-fetal and neonatal medicine. 2010; 23(9): 1014-1018.

Chan T, Chen Y, Lee CH, Chou FH, Wu LW, Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. Reproductive Sciences 2006; 13(5): 364-367

Lewandoski KC, Stojanovic N, Press M, Tuck SM, Szoland C, Bienkie Wicz. K, Vatish M. Elerated serum cereal of visfatin in gestational diabetes: Comparative study across various degrees of glucose tolerance. Diabetologica 2007; 50(5):1033-1037.

Telejko B, Kuzmicki M, Zonenberg A, Szamatowicz J,gorska M Visfatin in gestational diabetes: serum levels and MRNA expression in fat and placental tissue: Diabetes Research and clinical practice. 2009; 84(1): 68-75.

Haider DG, Schaller G, Kapiotis S, Maier C, Luger A Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. Journal of Clinical Research in Pediatric Endocrinology.2012;4(2):76-81

Hontzch J, Jasser-Nitche H, Grillitsch M, Suppar E. Children and adolescents with type I Diabetes mellitus having higher plasma visfatin levels than healthy control. European Society for Pediatric Endocrinology.

Haider DG Haider DG, Handisurya A, Storka Visfatin response to glucose is reduced in women with gestational diabetes mellitus. Diabetes Care 2007;30(7):1889-1891

Alexiodou K, Alexander K, Liatos S. Perra D. Differences in plasma apelin and visfatin levels between patients with Type 1 Diabetes and healthy subjects after acute hyperglycemia and invalin administration. Hormones 2012. 11C4 ): 444-450.

Brown JE, Onyango DJ, Ramanjanegu M, Ramanjanegu M, Corner AC, Patel ST, Danmore SJ,Randera S.Visfatin regulates insulin secretion,insulin receptor signaling and mRNA expressions of diabetes mellitus related gene in mouse pancreatic cells. Journal of molecular endocrinology.2010;44: 171-178

Tofighi A, Hanzezada S, Mehdzadeh Y, Zolfaghari M. Plasma visfatin level in women with type 2 diabetes compare the effect of aerobic and resistance and training.Research.2014;2(25):150-159

Rabo SA, Mohammed NA, Eissa SS, Ali AA. Serum visfatin in type 2diabetes mellitus.Egyptian J. Intern Med 2013;25:27-32

Shelbaya S, Shoeib N,Sedduk S,Makboul K,Abel Bi R, Fahyma E.study of adipocytes visfatin. Endocrine Abstracts.2011;25:160

Ahmed MB,Ismail MI,Meki AM.relation of osteoprotegrin,visfatin and ghrelin to metabolic syndrome in type 2 diabetes patients. International Journal of Health Science.2015;9(2):127-139

Osama S El-Shaer, Khaled M Belal, Hesham AI. Increased serum visfatin levels in patients with type 2 diabetic patients. Life Science Journal 2012; (93)

Drogu T, Sonmez TA, Tasci, Bozoghu E, Yilmaz M,gene H. Visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus andimpaired glucose tolerance. Diabetes Res Clin Pract.2007;76(1):24-29




DOI: http://dx.doi.org/10.7575/aiac.abcmed.17.05.02.05

Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2019 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine